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The neuroleptic malignant syndrome is a rare and 
potentially lethal reaction which is usually associated with 
the use of medications with antidopaminergic properties. 
This article describes the case of an elderly gentleman who 
developed the neuroleptic malignant syndrome after withdrawal 
of the anticholinergic agent benzhexol (trihexyphenidyl 
hydrochloride), which he was taking for Parkinson’s disease. 
The patient improved rapidly after treatment was restarted. 
This case adds to the evidence that antidopaminergic agents 
may not be necessary for the development of this syndrome, 
and increased awareness of this possibility is advisable in such 
circumstances. 
Case report
A 74 year old gentleman suffering from Hoehn and Yahr stage 
IV Parkinson’s disease was referred to our geriatric department for 
assessment and rehabilitation, complaining of worsening mobility. 
He was noted to have bradykinesia, mask-like facies, cog-wheeling, 
resting tremor and generalized rigidity.  He required help with 
feeding, bathing, dressing and mobilisation.  His past medical history 
was unremarkable and the rest of the examination was normal.  The 
following were his medications at the time: benzhexol (trihexyphenidyl 
hydrochloride) 4mg three times daily, co-amilozide (amiloride/
hydrochlorothiazide) 5mg/50mg daily, co-careldopa 220mg three times 
daily and citalopram 10mg daily.  Since anticholinergic treatment is 
relatively contraindicated in this age group, we planned to replace 
benzhexol in stepwise fashion with the non-ergot dopamine agonist 
ropinirole, thereby hoping to achieve better control of his Parkinson’s 
disease.  Figure 1 shows how the medications were titrated.  
Shortly after starting this switch, our patient started having 
episodes of dysphonia and stiffness.  He deteriorated gradually 
over a period of several days, becoming increasingly dependent and 
immobile despite the use of dispersible cobeneldopa in addition to his 
therapy. He became sweaty and tachycardic, and was found to have 
a fever (38oC) on two occasions.  He developed lead pipe rigidity 
(particularly in the neck and back muscles), dysphagia, drowsiness 
and mutism, and became incontinent of urine.  His creatine kinase 
was elevated (peak 1545U/L; MB-fraction 3%).  His leukocytes were 
8.4x109/mm3,  blood urea nitrogen 1.79mmol/L, creatinine 73µmol/L, 
sodium 125mmol/L, potassium 3.7mmol/L, albumin 39.1g/L, calcium 
0.50mmol/L, bilirubin 15µmol/L, alkaline phosphatase 78U/L, alanine 
transaminase 47U/L, free thyroxine 16pmol/L and thyroid stimulating 
hormone 0.63mU/L.  The ECG showed a right bundle branch block 
and T wave inversions in V1, V2, V3 and AVR, and remained unchanged 
on subsequent ECGs. Although meningitis was part of our differential 
diagnosis, a lumbar puncture was not considered necessary because the 
syndrome had developed insidiously, the pyrexia had been transient 
and his leukocytes were normal.  These symptoms developed within 
days of the cross-taper and conversion from benzhexol to ropinirole. 
The patient was diagnosed with a mild form of the neuroleptic 
malignant syndrome (NMS) using Levinson’s criteria.1-6 This reaction 
seemed to have been a consequence of benzhexol withdrawal,7 and 
his anticholinergic therapy was therefore restarted.  This resulted in 
prompt improvement within a couple of days, and normalisation of the 
creatine kinase.  The patient became independent with feeding again 
and was discharged home two months after admission.  He is now able 
to walk with a rollator frame with minimal assistance.  
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The pathogenesis of the neuroleptic malignant syndrome 
is unknown, but dopaminergic D2 receptor blockade in the 
hypothalamus and nigrostriatal track have been implicated, with 
altered thermoregulation and muscular rigidity respectively.8 
Some features of the neuroleptic malignant syndrome are also 
thought to be mediated by dysregulation of the sympathetic 
nervous system.  Co-existing biochemical imbalances, such as 
hypocalcaemia in our patient, can contribute to the development 
of the syndrome.  In cases related to atypical antipsychotic 
drugs, the condition is usually associated with milder degrees of 
hyperthermia and rigidity and the mortality is lower than with 
conventional antipsychotics.9  The syndrome is complex and 
unpredictable, and has also been documented upon smoking 
cessation.10 
Anticholinergic agents are useful in the treatment of 
Parkinson’s disease, but are relatively contraindicated in the 
elderly.  Advancing age is associated with an increased incidence 
of adverse reactions7, probably due to the increased prevalence 
of conditions such as prostatic hypertrophy, dehydration, 
inefficiency of homeostatic mechanisms and raised intraocular 
pressure.  
Benzhexol has a half life of one and a half hours5, while 
ropinirole is known to have a large volume of distribution.
[11] Our patient developed NMS during withdrawal despite a 
complementary increase in his dopaminergic treatment.  While 
there is some experience with switching between different 
dopamine agonists,11-13 there is no information in the literature 
concerning replacement of anticholinergic agents.  We would 
not like to give the impression that anticholinergics are a routine 
part of the management of the neuroleptic malignant syndrome, 
because they may, in fact, predispose patients to hyperthermia by 
their inhibitory effect on sweating.1-4, 7  In our patient, however, 
this reaction was precipitated by benzhexol withdrawal, and its 
reintroduction contributed to resolution. We advise clinicians 
to tail high doses of anticholinergic medications slowly, to keep 
patients well hydrated and nursed in a cool environment, and 
to be watchful for features of NMS. This episode adds to the 
evidence that antidopaminergic agents may not be necessary 
for the development of this syndrome.  
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Figure 1:  Dose changes of benzhexol and ropinirole 
(dosages apply to the cumulative dose administered over 
a 24 hour period)  
Figure 2:  Trend of creatine kinase from 
diagnosis day 1  
